ClinicalTrials.gov
public full text
Public Domain
A Study of Recombinant Human Erythropoietin Beta (NeoRecormon) in Anemic Cancer Participants Treated With Chemotherapy
This study will evaluate the efficacy and tolerability of subcutaneous (SC) or intramuscular (IM) recombinant human erythropoietin beta (r-HuEPO) in participants with anemia and histologically or cytologically confirmed cancer.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Treatment for Patients With Non-Small Cell Lung Cancer Who Developed Anemia Due to Chemotherapy#1096448
- Survey on the Treatment of Anemia Using Recombinant Human Erythropoietin 2 (STAR-2)#813365
- A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy#1048042
- Safety, Tolerability and Preliminary Efficacy of Engineered Red Blood Cell in Patients With Advanced Malignancies#860948
- Epoetin Beta in Patients Undergoing Chemotherapy for Solid Tumors#980461
Record · ID 841931
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive